Altered Lipid Profile in COVID-19 Patients and Metabolic Reprogramming

Abstract

BackgroundCoronavirus disease 2019 (COVID-19) is a global pandemic. Previous studies have reported dyslipidemia in patients with COVID-19. Herein, we conducted a retrospective study and a bioinformatics analysis to evaluate the essential data of the lipid profile as well as the possible mechanism in patients with COVID-19.MethodsFirst of all, the retrospective study included three cohorts: patients with COVID-19, a healthy population, and patients with chronic obstructive pulmonary disease (COPD). For each subject, serum lipid profiles in the biochemical data were compared, including triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). Furthermore, bioinformatics analyses were performed for exploring the biological or immunological mechanisms.ResultsIn line with the biochemical data of the three cohorts, the statistical result displayed that patients with COVID-19 were more likely to have lower levels of TC and HDL-C as compared with healthy individuals. The differential proteins associated with COVID-19 are involved in the lipid pathway and can target and regulate cytokines and immune cells. Additionally, a heatmap revealed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were possibly involved in lipid metabolic reprogramming. The viral proteins, such as spike (S) and non-structural protein 2 (Nsp2) of SARS-CoV-2, may be involved in metabolic reprogramming.ConclusionThe metabolic reprogramming after SARS-CoV-2 infections is probably associated with the immune and clinical phenotype of patients. Hence, metabolic reprogramming may be targeted for developing antivirals against COVID-19.

Deciphering the Relationship between SARS-CoV-2 and Cancer

“…This event is caused by the replication of SARS-CoV-2 for its survival and is modulated by the host immunity activated by the viral infection [71,74]. Several metabolic pathways and processes have been investigated by omics technologies and discovered as reprogrammed in hospitalized COVID-19 patients, including amino acid and lipid metabolism, carbohydrate and energy metabolism, and immune-related pathways [75][76][77][78][79].…”

Effects of a multi-professional intervention on body composition, physical fitness and biochemical markers in overweight COVID-19 survivors: a clinical trial

“…Similar responses were identified after 8 weeks of concurrent training in untrained men ( Ghahramanloo et al, 2009 ). The absence of differences between the moderate and severe COVID-19 groups could be explained because patients with COVID-19 may experience dysregulation of lipid profiles after COVID-19 ( Zhao et al, 2022 ). Another point related to hospitalized COVID-19 patients is linked with low values of HDL-c during hospitalization and after discharge ( Sampedro-Nuñez et al, 2021 ).…”

Short-term and long-term effects of coronavirus infection: A review

“…Один из мета-анализов показал, что у больных с внебольничной пневмонией в долгосрочной перспективе повышен риск сердечнососудистых и цереброваскулярных заболеваний, даже если на исходном уровне у них не было сердечно-сосудистых заболеваний (Corrales-Medina, Alvarez, Weissfeld et al 2015). Так, в течение 12 лет наблюдения за 25 людьми, переболевшими SARS, у 40% из них отмечены сердечно-сосудистые аномалии (Zhao, Wang, Duan 2022). Стоит подчеркнуть, что и другие Н. А. Соболева вирусные заболевания могут влиять на ССС, так сердечно-сосудистые аномалии отмечены время госпитализации у восьми пациентов с гриппом H7N9, причем они нормализовались только через 1 год наблюдения (Wang, Xu, Yang et al 2017).…”